Standard intravesical therapies for interstitial cystitis

Area of Science:

• Urology
• Gastroenterology

Background:

• Interstitial cystitis (IC) presents significant treatment challenges for both patients and physicians.
• The pathophysiology of IC remains poorly understood, hindering objective assessment of disease severity and progression.

Purpose of the Study:

• To review the current landscape of interstitial cystitis treatment, focusing on intravesical therapies.
• To highlight the limitations of existing intravesical treatments and the need for further research.

Main Methods:

• Review of current intravesical treatment modalities for interstitial cystitis.
• Discussion of the efficacy, drawbacks, and variability of responses to therapies like Clorpactin lavage and DMSO instillations.
• Identification of the lack of high-quality comparative studies, such as double-blind, placebo-controlled trials, for intravesical treatments.

Main Results:

• Intravesical therapy is considered the most successful approach for symptom relief in interstitial cystitis.
• Current intravesical therapies, including Clorpactin lavage and DMSO, have significant drawbacks, including unpredictable and variable responses, and the need for multiple treatments or anesthetics.
• There is a notable absence of rigorous, comparative clinical trials evaluating the primary intravesical treatments for IC.

Conclusions:

• Despite being the most effective symptomatic treatment, current intravesical therapies for interstitial cystitis are limited by unpredictable outcomes and side effects.
• Further research into the pathogenesis and causation of IC is crucial for developing improved and more specific intravesical therapies.
• Advances in understanding IC are expected to drive the development of novel and more effective treatment strategies.